Navigation Links
Plavix's New Generic Status Could Be Boon for Patients
Date:5/15/2012

By Steven Reinberg
HealthDay Reporter

TUESDAY, May 15 (HealthDay News) -- The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, will go off patent in the United States on Thursday, making it considerably more affordable.

Adherence rates will improve as a result, and fewer patients will suffer from preventable cardiovascular problems, said Dr. Gregg Fonarow, a professor of medicine and director of the Ahmanson-UCLA Cardiomyopathy Center in Los Angeles.

"This medication has helped millions of patients avoid fatal and non-fatal cardiovascular events," said Fonarow, who also is a spokesman for the American Heart Association. But its high cost has "contributed to patients not filling initial prescriptions for the drug and premature discontinuation of clopidogrel," he said.

Patients who stop taking the drug prematurely may then face catastrophic consequences, including fatal cardiovascular events and strokes, he added.

Plavix works by helping prevent platelets in the blood from sticking together to form clots. The drug usually is taken along with aspirin, which acts as a blood thinner to prevent heart attack and stroke.

Plavix commonly is used by patients with heart-related chest pain, unstable heart disease or those who have had a stent implanted to open a blocked artery.

"The most important impact of the availability of generics will be to reduce costs for patients and health systems where clopidogrel is already indicated," said Dr. Ralph Sacco, chairman of neurology at the University of Miami School of Medicine and former president of the American Heart Association.

The drug doesn't work for everyone, however. Some patients cannot metabolize it, which reduces its effectiveness.

In addition, new drugs are available that may be better than Plavix, Fonarow said.

"Newer antiplatelet agents, such as prasugrel (Effient) and ticagrelor (Brilinta), have been shown to be more [effective] than clopidogrel, and for many patients these [drugs] may be a better choice, despite higher cost," Sacco said.

Sales of Plavix, made by Bristol-Myers Squibb, topped $9 billion in 2011. A generic version, at a much lower cost, is expected to eat into those sales dramatically. The drug already is sold as a generic by Sanofi in much of the European Union, according to the Associated Press.

Plavix currently can cost almost $200 a month, according to published reports. Generic versions are expected to cost much less.

To keep patients using brand-name Plavix rather than a generic version, the manufacturer is offering coupons that will bring down the cost.

Plavix, even in a less expensive version, can't replace other clot-preventing drugs, such as warfarin, in certain patients.

For example, Plavix is not recommended for patients with an irregular heartbeat, called atrial fibrillation, who take blood thinners to prevent strokes. A 2009 report in the New England Journal of Medicine said patients with atrial fibrillation who took Plavix were at an unacceptably high increased risk of severe bleeding.

"For patients with atrial fibrillation, anticoagulants like warfarin (Coumadin), dabigatran (Pradaxa) and rivaroxaban (Xarelto) are indicated, and clopidogrel is not an appropriate substitute," Fonarow said.

More information

For more information on Plavix, visit the U.S. National Institutes of Health.

SOURCES: Ralph Sacco M.D., chairman of neurology, University of Miami Miller School of Medicine, and former president, American Heart Association; Gregg Fonarow, M.D., professor of medicine, director, Ahmanson-UCLA Cardiomyopathy Center, co-director, University of California-Los Angeles Preventative Cardiology Program; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Generic, Brand-Name Heart Drugs Seem to Have Same Effect on Thyroid
2. Variation in make-up of generic epilepsy drugs can lead to dosing problems
3. Use of $4 generic drug programs could save society billions of dollars, study shows
4. Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
5. Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
6. Generic drug may improve the effectiveness of cancer nanotherapies
7. Disparities in treatment of children in the emergency department based on their insurance status
8. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
9. Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer
10. IU study: Socioeconomic status more influential than race in determination of child abuse
11. Duration of RBC storage does not affect short-term pulmonary, immunologic, or coagulation status
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Plavix's New Generic Status Could Be Boon for Patients
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: